Unknown Cancer NIHR-supported project Digestion, Kidneys & Other Organs
An Interventional, Open-label, Randomized, Multicenter Phase 3 Study Of Pf-07220060 Plus Letrozole Compared To Cdk4/6 Inhibitor Plus Letrozole In Participants Over 18 Years With Hormone Receptor (Hr)-positive, Her2-negative Advanced/metastatic Breast Cancer Who Have Not Received Any Prior Systemic Anti-cancer Treatment For Advanced/metastatic Disease
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Sacha Howell (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
An interventional, open-label, randomized, multicenter phase 3 study of pf-07220060 plus fulvestrant compared to investigator's choice of therapy in participants over 18 years of age with hormone receptor-positive, her2-negative advanced/metastatic breast cancer whose disease progressed after prior cdk 4/6 inhibitor based therapy
A Randomised, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer.
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Randomised Open-label Phase II study of induction standard of care Fulvestrant and CDK4/6 inhibition with the Addition of Ipatasertib in Metastatic ER+/HER2- breast cancer patients without ctDNA suppression
A randomized, multicenter, doubleblind, placebo-controlled phase iii study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in patients with her2-positive and pd-l1-positive locally advanced or metastatic breast cancer who have received prior trastuzumab- (+/- pertuzumab) and taxane-based therapy
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know